Progerin regulates actin cytoskeletal remodeling and inhibits EMT and metastasis in triple‑negative breast cancer cells.
Progerin, a mutant protein, surprisingly halts the spread of aggressive triple-negative breast cancer by restructuring the cell's internal skeleton and suppressing the epithelial-mesenchymal transition, a key driver of metastasis. This discovery could lead to new targeted ther...
This study investigated the effects of progerin, a mutant form of the lamin A protein, on triple-negative breast cancer (TNBC) cells. Progerin overexpression was found to significantly inhibit TNBC cell migration, invasion, and adhesion, without affecting cell senescence or proliferation. Mechanistically, progerin altered the organization of the actin cytoskeleton and reduced the expression of mesenchymal markers, while increasing the epithelial marker E-cadherin. These findings suggest that progerin can suppress the epithelial-mesenchymal transition, a crucial process in tumor metastasis. The study provides valuable insights into potential molecular targets for the development of new therapies for this aggressive form of breast cancer, which often has a poor prognosis.